Identification of the Thrombogenic Patient: Bedside Testing and Biomarker Analysis

The early identification of the "at risk" patient for cardiovascular events will enhance the personalized antithrombotic treatment strategies. It can be facilitated by simultaneous assessment of biomarkers of inflammation, endothelial dysfunction, coagulation and functional analyses of platelets and platelet-fibrin clot formation. In recent years, novel biomarkers have been identified and new point-of-care assays have been developed.

Thursday September 7, 2017
11:00 AM – 12:00 PM
MR5 3005

Refreshments Served
Hosted by: Weibin Shi